Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma

Clinical and Translational Oncology

Volumn 12, Issue 5, 2010, Pages 384-386

  Galán, Laura ^a   Sánchez, Antonio C ^a   Cantos, Blanca ^a   Provencio, Mariano ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Chemotherapy; Lymphocyte predominant Hodgkin's lymphoma; Rituximab

Indexed keywords

BLEOMYCIN; CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; DACARBAZINE; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINBLASTINE;

AGED; ARTICLE; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; FOLLICULAR DENDRITIC CELL; HUMAN; LYMPHADENOPATHY; MONOTHERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR BIOPSY; TUMOR VOLUME; WEIGHT REDUCTION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; RECURRENCE;

EID: 77955977644     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0521-9     Document Type: Article

References (12)

1. Nogová L, Rudiger T, Engert A (2006) Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology 2006:266-272
2. Feugier P, Labouyrie E, Djeridane M et al (2004) Comparison of initial characteristics and longterm outcome of patients with lymphocytepredominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 104:2675-2681
3. Nogová L, Reineke T, Josting A et al (2005) Lymphocyte-predominant and classical Hodgkin's lymphoma - comparison of outcomes. Eur J Haematol 66:106-110
4. Rehwald U, Schulz H, Reiser M et al (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101:420-424
5. Schulz H, Rehwald U, Morschhauser F et al (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109-111
6. Ekstrand BC, Lucas JB, Horwitz SM et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285-4289
7. Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783
8. Hainsworth JD, Litchy S, Burris HA et al (2002) Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267
9. van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301
10. Horning SJ, Bartlett NL, Breslin S et al (2007) Results of a prospective phase II trial of limited and extended Rituximab treatment in nodular lymphocyte-predominant Hodgkin's disease (NLPHD) [ASH Annual Meeting Abstracts] Blood 110:644
11. Azim HA Jr, Pruneri G, Cocorocchio E et al (2009) Rituximab in lymphocyte-predominant Hodgkin's disease. Oncology 76:26-29
12. Maeda LS, Advani RH (2009) The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 21:397-400